TIDMAMYT
RNS Number : 3870S
Amryt Pharma PLC
05 November 2019
5 November 2019
AIM: AMYT
Euronext Growth: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Grant of Options and Notification of Transactions by Persons
Discharging Managerial Responsibilities
Amryt announces that the Remuneration Committee has approved the
grant of 10,215,400 share options ("Options") to subscribe for
ordinary shares of 6p each in the Company ("Shares") under the
Employee Share Option Plan 2019 (the "Plan") to Joe Wiley, CEO, and
Rory Nealon, CFO, details of which are set out in the table
below.
The Options have an exercise price of GBP1.215p ("Exercise
Price"). These options may be exercised as follows:
-- 25% of the total Options granted may be exercised 12 months
after the date of grant;
-- a further 25% of the total Options granted may be exercised
24 months after the date of grant; and
-- the balance of the Options may be exercised 36 months
after the date of grant.
All Options are subject to change of control provisions and
expire on the seventh anniversary of their grant.
Following the grants of these options, the following Director
and Company Secretary have the following options:
Director / Company Options granted Total Options now
Secretary held
Joe Wiley 5,777,900 6,437,460
---------------- ------------------
Rory Nealon 4,437,500 4,826,823
---------------- ------------------
PDMR Dealings
The notification of dealing forms for each Director/Company
Secretary can be found below. This announcement is made in
accordance with Article 19 of the EU Market Abuse Regulation
596/2014.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Joe Wiley
------------------------------------- -----------------------------------------------
2. Reason for the notification
--------------------------------------------------------------------------------------
a) Position / status Director
------------------------------------- -----------------------------------------------
b) Initial notification Initial notification
/ amendment
------------------------------------- -----------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name Amryt Pharma plc
------------------------------------- -----------------------------------------------
b) Legal entity identifier 213800YNUJEOJ84L4T95
------------------------------------- -----------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.06 each
financial instrument,
type of instrument
Identification code ISIN: GB00BKLTQ412
------------------------------------- -----------------------------------------------
b) Nature of the transaction Grant of options under the Employee
Share Option Plan 2019 with an exercise
price of GBP1.215 to purchase 5,777,900
ordinary shares.
------------------------------------- -----------------------------------------------
c) Currency British Pounds
------------------------------------- -----------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- ---------------------- --------------------
N/A 5,777,900
----------------------------------------------------------------- --------------------
e) Aggregated information
* Aggregated volume 5,777,900
N/A
* Aggregated price
------------------------------------- -----------------------------------------------
f) Date of the transaction 5 November 2019
------------------------------------- -----------------------------------------------
g) Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Rory Nealon
------------------------------------- -----------------------------------------------
2. Reason for the notification
--------------------------------------------------------------------------------------
a) Position / status PDMR - CFO and Company Secretary
------------------------------------- -----------------------------------------------
b) Initial notification Initial notification
/ amendment
------------------------------------- -----------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name Amryt Pharma plc
------------------------------------- -----------------------------------------------
b) Legal entity identifier 213800YNUJEOJ84L4T95
------------------------------------- -----------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.06 each
financial instrument,
type of instrument
Identification code ISIN: GB00BKLTQ412
------------------------------------- -----------------------------------------------
b) Nature of the transaction Grant of options under the Employee
Share Option Plan 2019 with an exercise
price of GBP1.215 to purchase 4,437,500
ordinary shares.
------------------------------------- -----------------------------------------------
c) Currency British Pounds
------------------------------------- -----------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- ---------------------- --------------------
N/A 4,437,500
----------------------------------------------------------------- --------------------
e) Aggregated information
* Aggregated volume 4,437,500
N/A
* Aggregated price
------------------------------------- -----------------------------------------------
f) Date of the transaction 5 November 2019
------------------------------------- -----------------------------------------------
g) Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Enquiries:
Amryt Pharma plc +353 (1) 518 0200
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
NOMAD and Joint Broker
Edward Mansfield, Mark Percy, Daniel Bush,
John More
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Daragh O'Reilly
Consilium Strategic Communications +44 (0) 20 3709 5700
Amber Fennell, Matthew Neal, Nicholas
Brown
LifeSci Advisors, LLC +1 (212) 915 2564
Tim McCarthy
About Amryt
Amryt is a biopharmaceutical company focused on developing and
delivering innovative new treatments to help improve the lives of
patients with rare and orphan diseases. Amryt comprises a strong
and growing portfolio of commercial and development assets.
Amryt's commercial business comprises two orphan disease
products.
Juxtapid(R)/ Lojuxta(R) (lomitapide) is approved as an adjunct
to a low-fat diet and other lipid-lowering medicinal products for
adults with the rare cholesterol disorder, Homozygous Familial
Hypercholesterolaemia ("HoFH") in the US, Canada, Columbia,
Argentina and Japan (under the trade name, Juxtapid(R)) and in the
EU (under the trade name, Lojuxta(R)). HoFH is a rare genetic
disorder which impairs the body's ability to remove low density
lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood,
typically leading to abnormally high blood LDL cholesterol levels
in the body from before birth - often ten times more than people
without HoFH - and subsequent aggressive and premature
cardiovascular disease.
Myalept(R) / Myalepta(R) (metreleptin) is approved in the US
(under the trade name, Myalept(R)) as an adjunct to diet as
replacement therapy to treat the complications of leptin deficiency
in patients with congenital or acquired generalized lipodystrophy
(GL) and in the EU (under the trade name, Myalepta(R)) for the
treatment of leptin deficiency in patients with congenital or
acquired GL in adults and children two years of age and above and
familial or acquired partial lipodystrophy (PL) in adults and
children 12 or over for whom standard treatments have failed to
achieve adequate metabolic control. Metreleptin is also approved
for lipodystrophy in Japan. Generalised and partial lipodystrophy
are rare disorders characterised by loss or lack of adipose tissue
resulting in the deficiency of the hormone leptin, produced by fat
cells and are associated with severe metabolic abnormalities
including severe insulin resistance, diabetes, hypertriglyceridemia
and fatty liver disease.
Amryt's lead development candidate, AP101 (Oleogel-S10), is a
potential treatment for the cutaneous manifestations of
Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin
disorder affecting young children and adults for which there is
currently no approved treatment. It is currently being studied in a
Phase 3 clinical trial and recently reported that unblinded interim
efficacy data supported continuation of the study with a modest
increase in sample size and unblinded interim safety data allowed
the inclusion of children from as young as 21 days old. AP101 has
been granted FDA Pediatric Rare Disease Designation and has also
received a Fast Track Designation from the FDA. The European and US
market opportunity for EB is estimated by the Directors to be in
excess of $1 billion.
In March 2018, Amryt in-licenced a pre-clinical gene-therapy
platform technology, AP103, which offers a potential treatment for
patients with Recessive Dystrophic Epidermolysis Bullosa, a subset
of EB, and is also potentially relevant to other genetic
disorders.
For more information on Amryt, including products, please visit
www.amrytpharma.com
This announcement contains inside information for the purposes
of article 7 of the Market Abuse Regulation (EU) 596/2014
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFSEFAIFUSEFF
(END) Dow Jones Newswires
November 05, 2019 13:16 ET (18:16 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024